This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.
FIGO stage I-II with a known BRCA1/2 mutation (germline/gBRCA or somatic/tBRCA)
FIGO stage III-IV of any histology
Women aged ≥18 years of age at the time of diagnosis
Patients intended for platinum-based chemotherapy treatment
Non-epithelial ovarian cancer, borderline tumors, or mucinous histology
Patients with FIGO stage I-II, BRCAwt ovarian cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Lead sponsor